share_log

B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1

Benzinga ·  Dec 26, 2023 06:56

B of A Securities analyst Jason Zemansky downgrades AlloVir (NASDAQ:ALVR) from Buy to Underperform and lowers the price target from $17 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment